⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RGNX News
REGENXBIO Inc.
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
prnewswire.com
RGNX
Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas
globenewswire.com
GSK
RGNX
OMER
XENE
NMRA
Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas
globenewswire.com
GSK
RGNX
OMER
XENE
Muscular Dystrophy Association’s Legacy Awards Honor Innovators in Clinical and Scientific Research, and Community Impact at the 2026 MDA Clinical & Scientific Conference in March
globenewswire.com
ARGX
BIIB
BBIO
NVS
RGNX
SCHR
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
prnewswire.com
RGNX
CoEffex Launches to Redefine Leadership Development with Data-Driven Coaching for High Growth Companies
prnewswire.com
GNK
NVS
RGNX
REGENXBIO to Participate in Upcoming Investor Conference
prnewswire.com
RGNX
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
prnewswire.com
RGNX
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
prnewswire.com
RGNX
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
prnewswire.com
RGNX